Results 111 to 120 of about 111,871 (303)

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. [PDF]

, 2019
Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired resistance.
A Hübner, AB D’Assoro, AJ Lee, AN Hata, Andrei Goga, Andrew D. Simmons, Angel Ku, AS Nikonova, Ashley Maynard, B Melichar, CA Eberlein, CK Lee, CM Blakely, CM Blakely, Collin M. Blakely, D Ercan, DB Costa, F Varghese, Frank McCormick, Golzar Hemmati, Gregor Krings, Hayley J. Donnella, Henry J. Haringsma, J Chen, J Fu, Jacqueline Galeas, JJ Chabon, Jonathan Kuhn, Julia Rohrberg, Julia Rotow, K Shien, Khyati N. Shah, KS Thress, L Li, Liliane Robillard, LV Sequist, LV Sequist, M Moustafa-Kamal, M Ramirez, Maria M. Martins, MJ Niederst, MS Cragg, MW Karaman, OJ Gruss, PA Jänne, R Rosell, RA Burrell, Roma Bhatt, S Anand, S Stewart, Sophie Dumont, Sourav Bandyopadhyay, SV Sharma, Swati Kaushik, T Sharifnia, TC Chou, TG Bivona, TG Bivona, Thomas C. Harding, TM Kim, Trever G. Bivona, V Bavetsias, Victor Olivas, Victoria E. Wang, Y Zhou, Z Piotrowska, Z Yang   +66 more
core   +1 more source

DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling‐Mediated Anti‐tumor Immunity

Advanced Science, EarlyView.
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang, Xi Dai, Shuaihu Li, Yingxue Chen, Yaxin Yu, Lin Wang, Kun Liu, Shuhan Lyu, Chongyang Li, Yihua Sun, Fei Li   +10 more
wiley   +1 more source

PARP inhibitor combinations in prostate cancer

Therapeutic Advances in Medical Oncology, 2020
Polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors cause deoxyribonucleic acid (DNA) damage that can be lethal to cells with deficient repair mechanisms.
Carmel Pezaro
doaj   +1 more source

Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy [PDF]

, 2014
BRCA1, a key factor in homologous recombination repair may also regulate base excision repair (BER). Targeting BRCA1-BER deficient cells by blockade of ATM and DNA-PKcs could be a promising strategy in breast cancer.
Abdel-Fatah, TMA, Agarwal, D, Albarakati, N, Alsubhi, N, Arora, A, Ball, G, Caldas, C, Chan, S, Doherty, R, Ellis, IO, Green, A, Madhusudan, S, Moseley, P, Perry, C, Rakha, EA, Russell, R, Seedhouse, C   +16 more
core   +1 more source

Metabologenomic Hallmark‐Based Discovery of Bacterial Thioamides as a New Lead against Drug‐Resistant Pancreatic Cancer

Advanced Science, EarlyView.
A targeted metabologenomic strategy integrating genomic and metabolomic hallmarks enabled the discovery of two new thioamides, thiogochangamides A and B, from bacteria. Their absolute configurations, previously unresolved within the thioviridamide family, were fully assigned through various chemical derivatizations and computational analysis ...
Young Eun Du, Eun Seo Bae, Thinh T. M. Bui, Seok Beom Lee, Dahan Kim, Jin‐Gyeong Park, Yongjoo Park, Soo Yeon Park, Sangwook Kang, Beomsu Lee, Daniel Shin, Yun Pyo Kang, In‐Gyun Lee, Dae‐Duk Kim, Seokhee Kim, Suckchang Hong, Kyuho Moon, Sang Kook Lee, Dong‐Chan Oh   +18 more
wiley   +1 more source

Delivery of Pleckstrin‐Homology Domains Suppresses PI3K/Akt Signaling and Breast Cancer Metastasis

Advanced Science, EarlyView.
Current therapies curb tumor growth but not metastasis. Obscurin, a giant metastasis suppressor lost in breast cancer, restrains PI3K/Akt signaling but is impractical to restore. We deploy a mini‐obscurin, comprising the obscurin‐PH‐domain, which sequesters PI3K‐p85, potently suppressing invasion and metastasis.
Matthew Eason, Anindya Sen, Suhan Cho, Se Jong Lee, Keyata Thompson, Md Musavvir Mahmud, Poornima Dubey, Talia Guardia, Anthony Kim, Stuart Martin, Nathan Wright, Konstantinos Konstantopoulos, Aikaterini Kontrogianni‐Konstantopoulos   +12 more
wiley   +1 more source

Exploring the radiochemistry of PARP inhibitors: a new era in therapy and imaging

EJNMMI Radiopharmacy and Chemistry
Background Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as a promising class of therapeutics, particularly in the treatment of cancers with defective DNA repair mechanisms, such as those with breast cancer genes (BRCA) mutations.
Gianluca Destro, Rebecca Rizzo, Chiara Rua, Raha Rouhbakhsh Azimi, Silvia Morbelli   +4 more
doaj   +1 more source

Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas [PDF]

, 2018
FDA-approved BRAF inhibitors produce high response rates and improve overall survival in patients with BRAF V600E/K-mutant melanoma, but are linked to pathologies associated with paradoxical ERK1/2 activation in wild-type BRAF cells.
Aplin, Andrew E., Berger, Adam C., Bollag, Gideon, Davies, Michael A., Goldberg, Allison F., Hartsough, Edward J., Knudsen, Karen E., Kugel, Curtis H., Purwin, Timothy J., Schiewer, Matthew J., Vido, Michael J.   +10 more
core   +1 more source

PAF Triggered Pyroptotic NETosis Aggravates Myocardial Ischemia/Reperfusion Injury

Advanced Science, EarlyView.
Platelet activating factor (PAF) secreted by cardiomyocytes during MI/R, drives NETs formation and subsequent NETosis. PAF/NETosis signaling activation is an initiative and causal factor in driving MI/R injury. This study identifies dapagliflozin as a potent NETosis inhibitor, and demonstrates that manipulating PAF‐NETosis signal by dapagliflozin or ...
Jiawei Wu, Shule Zhang, Ruofan Du, Lina Kang, Guodong Zhao, Xue Bao, Haochi Yang, Ziqing Xie, Tianyu He, Huiyong Sun, Haiping Hao, Lijuan Cao   +11 more
wiley   +1 more source

PARP inhibitors for prostate cancer

Seminars in Oncology
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread use of genomic testing in all patients with mCRPC.
Ossian Longoria, Nick Beije, Johann S. de Bono   +2 more
openaire   +2 more sources